
Please try another search
The subfund invests mainly in stocks from the Health Care sector (medical equipment, pharmaceuticals, biotechnology, etc.) listed on the exchanges of the three major regions (Asia, Europe, and America).
Name | Title | Since | Until |
---|---|---|---|
Servaas Michielssens | - | 2024 | Now |
Biography | Servaas Michielssens has been a Senior Analyst at Candriam since 2016, and became co-manager of the Biotechnology and Oncology strategy since November 2018. He began his career as a PhD student at the University of Leuven Belgium in 2007, where he obtained his PhD in science in 2011. In 2012 he became a postdoctoral scholar at the Max Planck Institute for Biophysical Chemistry in Germany. Servaas holds a master degree in chemistry from the University of Leuven, Belgium and a PhD in science from the same university. Servaas is also a CFA charterholder. | ||
Pierre Vaurice | Analyst Equities - Thematic Medtechnologies | 2022 | Now |
Biography | Due to European regulatory GDPR guidelines, Candriam cannot provide personal details as education or professional background to databases outside Europe.Information available on request only. | ||
Rudi Van den Eynde | Senior Portfolio Manager, Equities | 2019 | 2024 |
Biography | Due to European regulatory GDPR guidelines, Candriam cannot provide personal details as education or professional background to databases outside Europe. Information available on request only. | ||
Frederic Buzare | - | 2007 | 2014 |
Management Team | - | 1997 | 2007 |
Biography | Team Managed |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review